Faripiravir produced by the Government Pharmaceutical Organization (GPO) has received registration with the Food and Drug Administration (FDA) and should be able to begin distribution to those in need from August, with the organization also closing deals to sell Moderna brand COVID-19 vacine doses to a private hospital ahead of its signing of a purchase agreement with Zuellig Pharma on July 23.
Deputy Director of the GPO Sirikul Methivirangsan, has advised the public that the organization has secured deals to sell Moderna brand vaccine to 285 private hospitals and will commence signing contracts on July 21, 2021.
Around July 23, 2021, the GPO will sign a purchase deal with Zuellig Pharma, representing Moderna. Ahead of the scheduled signing, it will secure 5 million doses of the vaccine for Thailand by the fourth quarter of this year and the first quarter of 2022.
Meanwhile, 200 mg. Favipiravir pills, developed and produced by the GPO under the commercial name Favir, have received FDA registration and should soon be available for distribution to COVID-19 patients.
Initially, the organization will produce over 2 million pills monthly before increasing production in accordance with demand. The GPO’s work will significantly reduce the cost of the drug, which up until now had to be imported.
Deputy Director of the GPO Sirikul Methivirangsan, has advised the public that the organization has secured deals to sell Moderna brand vaccine to 285 private hospitals and will commence signing contracts on July 21, 2021.
Around July 23, 2021, the GPO will sign a purchase deal with Zuellig Pharma, representing Moderna. Ahead of the scheduled signing, it will secure 5 million doses of the vaccine for Thailand by the fourth quarter of this year and the first quarter of 2022.
Meanwhile, 200 mg. Favipiravir pills, developed and produced by the GPO under the commercial name Favir, have received FDA registration and should soon be available for distribution to COVID-19 patients.
Initially, the organization will produce over 2 million pills monthly before increasing production in accordance with demand. The GPO’s work will significantly reduce the cost of the drug, which up until now had to be imported.